Chindex International, Inc. Reports Financial Results for Second Quarter and First Half of 2014

BETHESDA, Md., Aug. 11, 2014 /PRNewswire/ -- Chindex International, Inc. (NASDAQ: CHDX), an American healthcare company providing premium quality healthcare services in China through the operations of United Family Healthcare ("UFH"), a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the second quarter ended June 30, 2014.

Second Quarter 2014 Financial Highlights

  • Revenue from healthcare services increased 21% to $55.5 million from $46.0 million in the prior year period.
  • Adjusted EBITDA increased 42% to $10.3 million from $7.3 million in the prior year period.
  • Income from operations decreased 3% to $1.8 million from $1.9 million in the prior year period.
  • Net loss was $693,000, or $(0.04) per diluted share, compared to net loss of $122,000, or $(0.01) per diluted share, in the prior year period.
  • Merger transaction expenses were $2.0 million.

Roberta Lipson, President and CEO of Chindex, commented, "The second quarter was characterized by continued expansion of our network of hospitals and clinics, and broadening of our scope of services. The United Family Healthcare Financial Street Clinic opened in May 2014, representing our first facility in western Beijing. Along with our Haidian hospital, which is currently under construction, this is part of our focused effort to reach more patients in Beijing's finance and technology centers."

"Our results this quarter reflect substantial development expenses from these expansion activities as well as expenses related to our pending merger. We are continuing our efforts to strategically expand our network and service scope to bring international-standard, premium healthcare services to more people in China," concluded Ms. Lipson.

Business Updates

As previously announced, the Company has entered into an amended and restated merger agreement (the "Amended Agreement") with a buyer consortium (the "Buyer Consortium") comprised of an affiliate of TPG, an affiliate of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Ms. Lipson and a merger subsidiary. Pursuant to the Amended Agreement, at the effective time of the merger, the Company will become privately owned and unaffiliated stockholders will be entitled to receive merger consideration of $24.00 per share. As previously announced, the merger is not subject to a financing condition and, assuming the satisfaction of conditions specified in the Amended Agreement, the Company expects the merger to close in the second half of 2014.

Second Quarter 2014 Financial Results

Second quarter 2014 revenue from healthcare services increased 21% to $55.5 million from $46.0 million in the prior year period. These results reflect growth of inpatient and outpatient volume across the United Family Healthcare network as well as increased contributions from the Company's new facilities in Beijing. Overall, outpatient services contributed 57% of revenue while inpatient services contributed 43%, compared with 58% and 42%, respectively, in the prior year period. By service line, surgical services contributed 22.5%; OB/GYN contributed 13.4%; pediatrics contributed 8.2%; ancillary services, including laboratory, radiology and pharmacy, contributed 27.7%; internal medicine contributed 3.4%; emergency room contributed 2.9%; dental contributed 2.8%; family medicine 2.2% and other clinical service lines contributed 16.9% of revenue.

Operating expenses in the second quarter 2014 increased 22% to $53.6 million from $44.1 million in the prior year period. The increase was primarily driven by salaries, wages and benefits expenses, which increased 15% over the second quarter 2013 from $26.8 million to $30.8 million, and merger transaction expenses of $2.0 million, which include fees for legal and other professional services related to the Company's pending merger. The increase in salaries, wages and benefits reflects both an increase in headcount to support revenue growth and development activities for new facilities and services and a new government mandate on increased social benefits. Development, pre- and post-opening and start-up expenses were $3 million, the same as in the prior year period. These expenses were driven by development projects, including expansion of the outpatient clinics at Beijing United Family Hospital and construction of new hospitals in Beijing and Qingdao.

Adjusted EBITDA in the second quarter of 2014 increased 42% to $10.3 million, compared to $7.3 million in the prior year period. The Adjusted EBITDA results show continued growth of the Company's core primary care business as well as growth from recently-expanded surgical services.

Income from operations was $1.8 million, compared to $1.9 million in the prior year period.

The Company recorded a $2.2 million provision for taxes in the second quarter of 2014, compared to the tax provision of $1.7 million in the prior year period. As in past quarters, the current period provision continued to be impacted by a higher tax rate due to losses in development and start-up entities for which the Company cannot currently recognize tax benefits.

Net loss for the quarter ended June 30, 2014 was $693,000, or $(0.04) per diluted share, compared to net loss of $122,000, or $(0.01) per diluted share, in the prior year period. The Company's minority interest in CML represented a loss of $174,000 during the recent period compared to a loss of $387,000 in the prior year period. For the second quarter of 2014, weighted average diluted shares outstanding were 17.8million.

As of June 30, 2014, the Company had $39.3 million in unrestricted cash and cash equivalents.

First Half 2013 Financial Results

During the first half of 2014, revenue from healthcare services increased 20% to $105.3 million from $87.5 million in the prior year period, reflecting growth of inpatient and outpatient volume across the United Family Healthcare network as well as increased contributions from the Company's new facilities in Beijing. Outpatient services contributed 58% of revenue and inpatient services contributed 42% of revenue in the first half of 2014, which represents the same distribution as in the first half of 2013. By service line, surgical services contributed 20.6%, OB/GYN contributed 13.8%, pediatrics contributed 9.0%, ancillary services contributed 28.0%, internal medicine contributed 3.3%, emergency room contributed 2.9%, dental contributed 3.0%, family medicine 2.2% and other services contributed 17.2% of revenue.

Operating expenses for the first half of 2014 increased 26% to $105.0 million from $83.1 million in the prior year period. Development, pre-opening and start up expenses increased to $7.0 million from $5.4million in the prior year. Income from operations for the first half of 2014 was $374,000, compared to $4.5 million in the prior year period. This decrease largely reflects the $5.3 million in merger transaction expenses incurred in the first half of 2014 as compared to $192,000 in merger transaction expenses in the prior year period. Adjusted EBITDA was approximately $19.4million compared to $14.7 million in the prior year period. The Adjusted EBITDA results show continued growth of the Company's core primary care business as well as growth from recently-expanded surgical services.

Provision for taxes was $3.8 million, compared to $3.6 million in the prior year period. Net loss was $4.2 million, or $(0.24) per diluted share, compared to net loss of $184,000, or $(0.01) per diluted share, in the first half of 2013. For the first half of 2014 ended June 30, 2014, weighted average diluted shares outstanding were 17.8million.

Chindex Medical Limited

For Chindex Medical Limited (CML), a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Chindex International, Chindex recognized its 30% interest in CML's net loss using the equity method of accounting since the acquisition of Alma Lasers, Inc. on May 27, 2013.

In the second quarter of 2014, Chindex recognized a loss of $174,000 for its equity interest in CML. For the first half of 2014, the Company recognized a loss of $524,000 million for its equity interest in CML.

The operating results of CML in the first half of 2014 continued to be negatively impacted by the overall slowdown in the capital medical equipment markets in China as a result of restructuring at the Ministry of Finance, uncertainty surrounding proposed reforms and the disruption to normal hospital purchasing activity due to the government campaign to improve compliance in the public hospitals' purchasing activities.

Non-GAAP Measures

The Company presents Adjusted EBITDA to better illustrate ongoing operational results. Adjusted EBITDA is defined as income (loss) before interest expense, interest and other income, income taxes, depreciation and amortization, and also excludes development, pre-opening and start-up expenses related to new and pending hospitals and clinics and equity in earnings (loss) of unconsolidated affiliate and nonrecurring transaction costs. The Company anticipates recurring development, pre-opening and start-up expense and notes that such expense is a basic element of the long term growth plan. Management believes that providing an Adjusted EBITDA analysis to investors is a helpful metric to better illustrate the Company's operations, including development plans, and changes in presentation from historical periods. The Company uses Adjusted EBITDA for business planning and other purposes. Other companies may calculate Adjusted EBITDA differently, and therefore Chindex's Adjusted EBITDA may not be comparable to similarly titled measures of other companies. Adjusted EBITDA is not a measure of financial performance under U.S. generally accepted accounting principles (GAAP), and should not be considered in isolation or as an alternative to net income (loss), cash flows from operating activities and other measures determined in accordance with GAAP. Items excluded from Adjusted EBITDA are significant and necessary components to the operations of the Company's business, and, therefore, Adjusted EBITDA should only be used as a supplemental measure of operating performance.

About Chindex International, Inc.

Chindex is an American healthcare company providing premium quality healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. United Family Healthcare currently operates in Beijing, Shanghai, Tianjin and Guangzhou with a future facility under construction in Qingdao. The Company also provides medical capital equipment and products through Chindex Medical Ltd., a joint venture company with manufacturing and distribution businesses serving both domestic China and export markets. With more than thirty years of experience, the Company's strategy is to continue its growth as a leading integrated health care provider in the Greater China region. Further Company information may be found at the Company's website at http://www.chindex.com.

Safe Harbor Statement

Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, updates and additions to those "Risk Factors" in the Company's interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.

Financial Summary Attached

CONTACT: ICR, Inc., Bill Zima, +86-10-6583-7511, +1-646-328-2510

 

CHINDEX INTERNATIONAL, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(in thousands except share and per share data)

(Unaudited)




Three months ended June 30,


Six months ended June 30,




2014


2013


2014


2013











Healthcare services revenue

$ 55,453


$ 45,977


$ 105,338


$ 87,542











Operating expenses









Salaries, wages and benefits

30,786


26,834


58,822


49,497


Other operating expenses

6,579


5,642


13,019


11,274


Supplies and purchased medical services

6,970


5,590


12,925


10,555


Bad debt expense

460


1,140


1,574


2,119


Depreciation and amortization

3,410


2,353


6,652


4,655


Lease and rental expense

3,371


2,410


6,636


4,771


Merger transaction expenses

2,035


109


5,336


192




53,611


44,078


104,964


83,063











Income from operations

1,842


1,899


374


4,479











 Other income and (expenses)









Interest income

226


241


451


489


Interest expense

(389)


(226)


(748)


(328)


Equity in loss of unconsolidated affiliate

(174)


(387)


(524)


(1,287)


Miscellaneous income - net

40


39


60


37











Income (loss) before income taxes

1,545


1,566


(387)


3,390

Provision for income taxes

(2,238)


(1,688)


(3,820)


(3,574)











Net loss


$ (693)


$ (122)


$ (4,207)


$ (184)











Net loss per common share - basic

$ (.04)


$ (.01)


$ (.24)


$ (.01)











Weighted average shares outstanding - basic

17,813,312


16,582,068


17,750,642


16,566,004











Net loss per common share - diluted

$ (.04)


$ (.01)


$ (.24)


$ (.01)











Weighted average shares outstanding - diluted

17,813,312


16,582,068


17,750,642


16,566,004

 

 


 

CHINDEX INTERNATIONAL, INC.

CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands, except share data)

(Unaudited)

 



June 30, 2014


December 31, 2013


ASSETS




Current assets:





Cash and cash equivalents

$ 39,340


$ 33,107


Restricted cash

1,272


1,286


Accounts receivable, less allowance for doubtful accounts of $15,775and $14,338, respectively

24,960


23,041


Receivables from affiliates

1,870


2,897


Inventories of supplies, net

2,975


2,781


Deferred income taxes

5,208


4,763


Other current assets

5,236


3,787


     Total current assets

80,861


71,662

Restricted cash and sinking funds

18,391


19,262

Investment in unconsolidated affiliate

33,559


34,178

Property and equipment, net

115,286


113,838

Noncurrent deferred income taxes

905


811

Other assets

4,186


4,817


     Total assets

$ 253,188


$ 244,568




LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:





Short-term debt

$ 4,336


$ 3,648


Accounts payable

12,567


11,705


Payable to affiliates

2,746


1,977


Accrued expenses

14,470


17,984


Other current liabilities

14,526


11,408


Income taxes payable

2,821


3,658


     Total current liabilities

51,466


50,380

Long-term debt

 

36,450


26,715

Long-term deferred rent

 

1,530


1,223

Long-term deferred tax liability

 

229


231


     Total liabilities

89,675


78,549

Commitments and contingencies




Stockholders' equity:





Preferred stock, $.01 par value, 500,000 shares authorized, none issued

-


-


Common stock, $.01 par value, 28,200,000 shares authorized, including





3,200,000 designated Class B:





Common stock – 17,100,747 and 16,934,753 shares issued and





outstanding at June 30, 2014 and December 31, 2013,





               respectively

171


169


           Class B stock – 1,162,500 shares issued and outstanding at





June 30, 2014 and December 31, 2013, respectively

12


12


Additional paid-in capital

143,489


140,809


Retained earnings

8,243


12,450


Accumulated other comprehensive income

11,598


12,579


       Total stockholders' equity

163,513


166,019


           Total liabilities and stockholders' equity

$ 253,188


$ 244,568

 



CHINDEX INTERNATIONAL, INC.

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)



Six months ended June 30,



2014


2013

OPERATING ACTIVITIES




Net loss

$ (4,207)


$ (184)

Adjustments to reconcile net loss to net cash provided by (used in)





operating activities: 





Depreciation and amortization

6,652


4,655


Inventory write down

3


10


Provision for doubtful accounts

1,351


2,119


Loss on disposal of property and equipment

9


8


Equity in net loss of unconsolidated affiliate

524


1,287


Deferred income benefit

(589)


(519)


Stock based compensation

2,209


2,234


Foreign exchange loss (gain)

237


(286)


Amortization of debt issuance costs

272


5


Amortization of debt discount

-


124

Changes in operating assets and liabilities:





Accounts receivable

(3,495)


(4,967)


Receivables from affiliates

1,027


(612)


Inventories of supplies

(224)


(425)


Other current assets and other assets

(1,191)


(2,257)


Accounts payable, accrued expenses, other current liabilities





and deferred rent

1,119


(4,232)


Payable to affiliates

769


(12)


Income taxes payable

(807)


(878)

Net cash provided by (used in) operating activities

3,659


(3,930)

INVESTING ACTIVITIES





Purchases of property and equipment

(9,137)


(5,899)

Net cash used in investing activities

(9,137)


(5,899)

FINANCING ACTIVITIES





Restricted cash from IFC RMB loan sinking funds

446


444


Restricted cash from Exim loan

252


-


Proceeds from debt

12,000


11,000


Repayment of debt

(1,469)


(800)


Repurchase of restricted stock for income tax withholding

(355)


(220)


Proceeds from exercise of stock options

828


114

Net cash provided by financing activities

11,702


10,538

Effect of foreign exchange rate changes on cash and cash equivalents

9


(87)

Net increase in cash and cash equivalents

6,233


622

Cash and cash equivalents at beginning of period

33,107


33,184

Cash and cash equivalents at end of period

$ 39,340


$ 33,806






Supplemental disclosures of cash flow information:




Cash paid for interest

$ 387


$ 57

Cash paid for taxes

$ 5,197


$ 5,005






Non-cash investing and financing activities consist of the following:




Change in property and equipment additions included in accounts




payable and payable to affiliates

$ (41)


$ 1,691

 

The table below reconciles our consolidated net (loss) income to Adjusted EBITDA (in thousands)

 


Three months ended June 30,


Six months ended June 30,


2014

2013


2014

2013







Consolidated net loss

($693)

($122)


($4,207)

($184)







Adjustments:






          Depreciation and amortization

3,410

2,353


6,652

4,655

          Provision for income taxes

2,238

1,688


3,820

3,574

          Interest expense

389

226


748

328

          Interest and other income, net

-266

-280


-511

-526

          Development, pre-opening and start-up expense

3,049

2,895


7,003

5,360

          Equity in loss of unconsolidated affiliate

174

387


524

1,287

          Nonrecurring transactions costs

2,035

109


5,336

192


11,029

7,378


23,572

14,870







Adjusted EBITDA

$10,336

$7,256


$19,365

$14,686

 

SOURCE Chindex International, Inc.



RELATED LINKS
http://www.chindex.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.